“Where do I start?”: Strategies for selecting the first dose for human clinical trials White Paper “Where do I start?”: Strategies for selecting the first dose for human clinical trials This guide to dose selection for first-in-human studies explains the conceptual framework, methods, and tools…CertaraDecember 22, 2020
Clinical Pharmacology Gap Analysis: Lessons Learned Blog Clinical Pharmacology Gap Analysis: Lessons Learned Clinical pharmacology gap analysis is a tool for outlining your drug program’s needs, prioritizing these…CertaraAugust 10, 2018
Metformin Treatment of Type 2 Diabetes Mellitus in Pregnancy: Update on Safety and Efficacy Publication Metformin Treatment of Type 2 Diabetes Mellitus in Pregnancy: Update on Safety and Efficacy CertaraApril 25, 2018
Using M&S to Evaluate Oncology Drug Dosing Blog Using M&S to Evaluate Oncology Drug Dosing There are numerous challenges in developing oncology drugs: (1) they are often very toxic which…CertaraApril 13, 2018
Using a Pharmacology to Payer Framework to Support Product Development Blog Using a Pharmacology to Payer Framework to Support Product Development Modeling and simulation (M&S) of complex systems has primarily advanced vertically in differing scientific domains…CertaraMarch 16, 2018
Cost-utility Analysis of Antiviral Use Under Pandemic Influenza Using a Novel Approach—Linking Pharmacology, Epidemiology and Heath Economics Publication Cost-utility Analysis of Antiviral Use Under Pandemic Influenza Using a Novel Approach—Linking Pharmacology, Epidemiology and Heath Economics CertaraMarch 1, 2018
Surveying the Lay of the Land for Modeling & Simulation for Global Regulatory Submissions Blog Surveying the Lay of the Land for Modeling & Simulation for Global Regulatory Submissions Analogous to how a geologist surveys the “lay of the land” to determine if oil…CertaraFebruary 16, 2018
Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach Publication Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach CertaraSeptember 15, 2017
Drug Asset Evaluation: Increasing “Probability of Success” of a Deal White Paper Drug Asset Evaluation: Increasing “Probability of Success” of a Deal Certara’s due diligence/asset evaluation teams are comprised of drug development and commercialization experts who advise…CertaraAugust 24, 2017
Investigational Drug Gap Analysis Brochure Investigational Drug Gap Analysis As the process of drug development has increased in cost and complexity, Certara has developed…CertaraAugust 14, 2017